Novo Nordisk taps Evotec to target chronic kidney disease

Novo Nordisk has signed up to work with Evotec on the discovery and development of chronic kidney disease (CKD) drugs. The deal comes two years after Novo Nordisk licensed a kidney disease prospect from Epigen Biosciences as part of its effort to expand into areas adjacent to its core diabetes business.